Cargando…

Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS

OBJECTIVE: To investigate the infection status of high-risk human papillomavirus (HR-HPV) E6/E7 mRNA in patients with a cytological diagnosis of “atypical squamous cells of undetermined significance” (ASCUS) and to analyze the pathogenic rate of different high-risk HPV subtypes combined with biopsy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xiu, Liu, Feifei, Zhang, Ya, Ma, Yingying, Yang, Linqing, Wang, Yunfei, Liu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503067/
https://www.ncbi.nlm.nih.gov/pubmed/37710244
http://dx.doi.org/10.1186/s12905-023-02599-3
_version_ 1785106444116295680
author Jin, Xiu
Liu, Feifei
Zhang, Ya
Ma, Yingying
Yang, Linqing
Wang, Yunfei
Liu, Ying
author_facet Jin, Xiu
Liu, Feifei
Zhang, Ya
Ma, Yingying
Yang, Linqing
Wang, Yunfei
Liu, Ying
author_sort Jin, Xiu
collection PubMed
description OBJECTIVE: To investigate the infection status of high-risk human papillomavirus (HR-HPV) E6/E7 mRNA in patients with a cytological diagnosis of “atypical squamous cells of undetermined significance” (ASCUS) and to analyze the pathogenic rate of different high-risk HPV subtypes combined with biopsy pathological results to provide a more accurate basis for managing ASCUS patients. METHODS: A total of 1387 patients with ASCUS and HPV E6/E7 mRNA positivity who were referred for colposcopy were retrospectively analyzed. They were divided into HPV16+, 18/45 + and other HR-HPV + groups premenopausal and postmenopausal groups. The pathological results of the biopsy were divided into the LSIL- group (including normal and low-grade squamous intraepithelial lesions) and the HSIL + group (including high-grade squamous intraepithelial lesions and higher lesions). SPSS was used for the analysis. RESULTS: The age group 31–40 years had the highest level of HPV16+, and HPV18/45 + was the highest in the 41–50 years group. The detection rates of HSIL + in the HPV16+, HPV18/45+, HPV 16/18/45 + and Other HR-HPV + groups were 48.4%, 18.8%, 43.9% and 15.0%, respectively. The infection rates of HPV16/18/45 in postmenopausal and premenopausal women were 42.4% and 34.3%, respectively. In the HPV18/45 group, the incidence of HSIL + was 30.0% in postmenopausal women and 15.0% in premenopausal women (P < 0.01). In the HPV 16 + and Other HR-HPV + groups, the incidence of HSIL + in postmenopausal patients was not significantly different from that in premenopausal patients. The incidence of cervical cancer in postmenopausal patients is significantly higher than that in premenopausal patients. CONCLUSIONS: Colposcopy referral or further biopsy is recommended for all ASCUS patients with HPV16/18/45E6/E7 mRNA positivity and postmenopausal patients with HR-HPVE6/E7 mRNA positivity. For premenopausal ASCUS patients with other HR-HPV E6/E7 mRNA positivity, colposcopy should be performed if possible, depending on the specific situation, to achieve early detection and diagnosis.
format Online
Article
Text
id pubmed-10503067
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105030672023-09-16 Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS Jin, Xiu Liu, Feifei Zhang, Ya Ma, Yingying Yang, Linqing Wang, Yunfei Liu, Ying BMC Womens Health Research OBJECTIVE: To investigate the infection status of high-risk human papillomavirus (HR-HPV) E6/E7 mRNA in patients with a cytological diagnosis of “atypical squamous cells of undetermined significance” (ASCUS) and to analyze the pathogenic rate of different high-risk HPV subtypes combined with biopsy pathological results to provide a more accurate basis for managing ASCUS patients. METHODS: A total of 1387 patients with ASCUS and HPV E6/E7 mRNA positivity who were referred for colposcopy were retrospectively analyzed. They were divided into HPV16+, 18/45 + and other HR-HPV + groups premenopausal and postmenopausal groups. The pathological results of the biopsy were divided into the LSIL- group (including normal and low-grade squamous intraepithelial lesions) and the HSIL + group (including high-grade squamous intraepithelial lesions and higher lesions). SPSS was used for the analysis. RESULTS: The age group 31–40 years had the highest level of HPV16+, and HPV18/45 + was the highest in the 41–50 years group. The detection rates of HSIL + in the HPV16+, HPV18/45+, HPV 16/18/45 + and Other HR-HPV + groups were 48.4%, 18.8%, 43.9% and 15.0%, respectively. The infection rates of HPV16/18/45 in postmenopausal and premenopausal women were 42.4% and 34.3%, respectively. In the HPV18/45 group, the incidence of HSIL + was 30.0% in postmenopausal women and 15.0% in premenopausal women (P < 0.01). In the HPV 16 + and Other HR-HPV + groups, the incidence of HSIL + in postmenopausal patients was not significantly different from that in premenopausal patients. The incidence of cervical cancer in postmenopausal patients is significantly higher than that in premenopausal patients. CONCLUSIONS: Colposcopy referral or further biopsy is recommended for all ASCUS patients with HPV16/18/45E6/E7 mRNA positivity and postmenopausal patients with HR-HPVE6/E7 mRNA positivity. For premenopausal ASCUS patients with other HR-HPV E6/E7 mRNA positivity, colposcopy should be performed if possible, depending on the specific situation, to achieve early detection and diagnosis. BioMed Central 2023-09-14 /pmc/articles/PMC10503067/ /pubmed/37710244 http://dx.doi.org/10.1186/s12905-023-02599-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jin, Xiu
Liu, Feifei
Zhang, Ya
Ma, Yingying
Yang, Linqing
Wang, Yunfei
Liu, Ying
Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title_full Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title_fullStr Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title_full_unstemmed Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title_short Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
title_sort diagnostic value of high-risk hpv e6/e7 mrna in patients with ascus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503067/
https://www.ncbi.nlm.nih.gov/pubmed/37710244
http://dx.doi.org/10.1186/s12905-023-02599-3
work_keys_str_mv AT jinxiu diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT liufeifei diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT zhangya diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT mayingying diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT yanglinqing diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT wangyunfei diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus
AT liuying diagnosticvalueofhighriskhpve6e7mrnainpatientswithascus